Cervical Cancer Survival Influenced by Presence of Diabetes Mellitus
the Cancer Therapy Advisor take:
Diabetes mellitus (DM) was determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer (CC), according to an article published online in the journal The Oncologist.
In this study, 2,946 patients diagnosed with primary stage 2-2A CC and received curative treatments between 2004 and 2008 were identified from the nationwide Taiwan Cancer Registry database. In total, 284 (9.6%) patients had DM.
Results showed patients with DM had significantly lower 5-year cervical cancer-specific survival (CSS) and overall survival (OS) rates compared to patients without DM (CSS: 85.4% vs. 91.5%; OS: 73.9% vs. 87.9%, respectively).
The investigators found that DM remained an independent unfavorable prognostic factor for CSS (aHR, 1.46) and OS (aHR, 1.55), after adjusting for clinicopathologic variables and comorbidities.
The study’s findings indicated that the risk of cancer recurrence and death in patients with early stage CC may be increased by DM, even after receiving curative treatments.
Diabetes mellitus determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol